GeoVax to Showcase Mpox Vaccine Development at Emerging Growth Conference
TL;DR
GeoVax Labs, Inc. to present at Emerging Growth Conference to discuss GEO-MVA vaccine for Mpox and smallpox, gaining insights into innovative immunotherapy.
GeoVax's lead clinical program, GEO-CM04S1, focuses on COVID-19 vaccine development with Phase 2 trials underway for various patient populations.
GeoVax's efforts in developing vaccines and therapies for infectious diseases and cancers aim to improve global health outcomes and treatment options.
Learn about GeoVax's novel vaccines for infectious diseases and solid tumor cancers, offering hope for improved immunotherapies and disease treatments.
Found this article helpful?
Share it with your network and spread the knowledge!
Biotechnology company GeoVax Labs will present its Mpox vaccine program at the Emerging Growth Conference on February 19, 2025. CEO David Dodd will discuss the development of GEO-MVA, a vaccine candidate targeting Mpox and smallpox, during a live, interactive online event.
The presentation provides an important opportunity for investors and the scientific community to gain insights into the company's infectious disease research. By focusing on Mpox and smallpox vaccine development, GeoVax is addressing critical public health challenges that have significant global implications.
During the 2:55 pm ET presentation, Dodd will share details about the GEO-MVA vaccine candidate, potentially highlighting its technological approach, development progress, and potential clinical applications. The conference will allow for real-time interaction, with attendees able to submit questions before and during the event.
This presentation comes as part of GeoVax's broader research strategy, which includes multiple clinical-stage programs in infectious diseases and oncology. The company's focus on developing vaccines for challenging infectious diseases demonstrates a commitment to addressing emerging global health threats.
Investors and interested parties can attend the conference online, with an archived webcast available for those unable to join the live event. The presentation represents an important opportunity to understand GeoVax's ongoing scientific and medical research efforts.
Curated from NewMediaWire
